Clinico-pathological and prognostic findings on 27 cases of medullary thyroid carcinoma.

##plugins.themes.academic_pro.article.main##

Azza Gabsi
Olfa El Amine El Hadj
Aida Goucha
Gritli Said
Besma Laabidi
Amor Gamoudi

Abstract

Introduction: Medullary thyroid carcinoma is a rare tumor accounting for less than 10% of thyroid neoplasm. This tumor is characterized by
important histological polymorphism which makes morphological diagnosis difficult and immunohistochemical study often necessary.


Objective: We aim to perform a retrospective review of clinical and pathological characteristics of medullary carcinoma. We will discuss the place
of immunohistochemistry in the positive diagnosis and as a prognostic factor.


Methods: patients with thyroid medullary carcinoma diagnosed in department of pathology at carcinologic institute between 1998 and 2013 were
retrospectively included. Clinic, radiologic and prognostic variables were assessed. Slides were reviewed for all the patients with confirmed
tumors.


Results: Twenty-seven patients with CMT were identified. The average age was 55 years with predominance of males. The average consultation
time was 16 months. The most common presentation symptom was a cervical lymph node.
Total thyroidectomy was performed in 23 patients. Tumor was nodular and unique in 22 cases. The average size was 2.1 cm. CMT was of mixed
type containing both medullary and papillary compound in four cases. Amyloid substance was present and abundant in 21cases. Positive staining
for calcitonin was observed in 16 cases. Distant metastasis or metastatic lymph nodes was observed in eight cases with an average period of
42 months. Radiotherapy was performed in fifteen cases and two patients received chemotherapy.


Conclusion: In the absence of amyloid deposits, immunohistochemical staining with calcitonin is useful to confirm the diagnosis. The prognosis
of this entity is more pejorative than papillary thyroid carcinoma.

Keywords:

Thyroid, Medullary Carcinoma, Calcitonin, Immunohistochemestry

##plugins.themes.academic_pro.article.details##

References

  1. Ball DW. Medullary thyroid carcinoma. 8Th edition. Philadelphia: Lippincott Williams & Wilkins. 2000.
  2. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006; 107 (9):2134-42.
  3. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. Jama. 2006; 295(18):2164-7.
  4. Viola D, Romei C, Elisei R. Medullary thyroid carcinoma in children. Endocr Dev. 2014;26:202-13.
  5. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf).2004;61(3):299-310.
  6. Guyetant S, Josselin N, Savagner F, Rohmer V, Michalak S, Saint-Andre JP. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients. Mod Pathol. 2003; 16(8):756-63.
  7. Niccoli-Sire P, Conte-Devolx B. Medullary thyroid carcinoma. Ann Endocrinol (Paris). 2007 ; 68(5):325-31.
  8. Wémeau JL, Sadoul JL, Herbomez M, Monpeyssen H, Tramalloni J, Leteurtre L et al. Guidelines of the French society of endocrinology for the management of thyroid nodules. Annales d'Endocrinologie. 2011 ; 72 :251-81.
  9. Bhanot P, Yang J, Schnadig VJ, Logrono R. Role of FNA cytology and immunochemistry in the diagnosis and management of medullary carcinoma: report of 6 cases and review of the literature. Diagn. Cytopathol. 2007; 35(5) : 285-92.
  10. Essig GF Jr, Porter K, Schneider D, Debora A, Lindsey SC, Busonero G, et al. Fine needle aspiration and medullary thyroid carcinoma: the risk of inadequate preoperative evaluation and initial surgery when relying upon FNAB cytology alone. Endocr Pract. 2013; 19:920-7.
  11. Marini F, Falchette A, Del Monte F. Multiple endocrine neoplasia type 2. Orphanet J Rare Dis. 2006; 14: 1-45.
  12. Mekni A, Limaiem F, Cherif K, Chelly I, Sahtout S, Bellil K et al. Valeur de l'examen extemporané en pathologie thyroïdienne: Étude rétrospective de 1534 examens consécutifs. La Presse Médicale. 2008; 37: 949-55.
  13. Guliana JM, Franc B et Duron F. Cancer médullaire de la thyroïde. Encycl Méd Chir. Endocrinologie-Nutrition.2001; 10 :15-30.
  14. Brandão LG, Cavalheiro BG, Junqueira CR. Prognostic influence of clinical and pathological factors in medullary thyroid carcinoma: a study of 53 cases. Clinics (Sao Paulo). 2009; 64(9):849-56.
  15. Rosai J, Carcangiu M, Delellis RA. Atlas of tumor pathology: tumor of the thyroid gland, 3rd series. Washington: Armed Forces Institute of Pathology. 1992: 207-58.
  16. Shukla S, Awasthi NP, Husain N. Papillary variant of medullary carcinoma thyroid. Indian J Pathol Microbiol. 2014 ; 57(1):151-2.
  17. Rios A, Rodriguez JM, Febrero B, Acosta JM, Terrogrosa N, Balsalobre M et al. Histological and immunohistochemical profile of sporadic and familial medullary thyroid carcinoma. Endocrinol NUTR. 2011; 58(10) 521-8.
  18. Liu H, Lin F. Application of immunohistochemistry in thyroid pathology. Arch Pathol Lab Med. 2015; 139(1):67-82.
  19. Ahmed SA, Snow-Bailey K, Highsmith WE, Sun W, Fenwick RG, Mao R. Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases. J Mol Diagn. 2005;7(2):283-8.
  20. Mohammed AA, El-Shentenawy A. Advanced thyroid cancers: new era of treatment. Med Oncol. 2014;31(7):49-58.
  21. Sun XS, Guevara N, Fakhry N, Sun RS, Marcy J, Santini J et al. Place de la radiothérapie externe dans les cancers de la thyroïde. Cancer /Radiothérapie. 2013;17: 233-43.
  22. Guillausseau JM, et le GETC. Place des thérapeutiques non chirurgicales dans le traitement des patients atteints de cancer médullaire de la thyroïde. Ann Endocrinol. 1996; 57: 33-40.
  23. Tuttle RM, Ganly I. Risk stratification in medullary thyroid cancer: Moving beyond static anatomic staging. Oral Oncol. 2013; 49:695-701.